Polish pharmaceutical company Biomed Lublin announced that it has finished production of the first batch of medicine made of plasma obtained from those who recovered from COVID-19 disease, Polandin.com reports.
The medicine, created via the process of the fractionation of plasma from patients who recovered or showed no symptoms of COVID-19 but were infected, contains specific anti-SARS-CoV-2 immunoglobulins. It will be released for non-commercial clinical trials in fourth quarter of 2020, according to the company.
“More than 3,000 samples of anti-SARS-CoV-2 immunoglobulin have been produced, which after the completion of the required quality tests, including product stability tests, will be submitted for clinical trials in four centres: in Lublin, Bytom, Białystok and Warsaw,” said Marcin Piróg, CEO of Biomed.
A total of 81,673 confirmed cases of the COVID-19 coronavirus infections were recorded in Poland as of the morning of September 23, which have resulted in 2,344 deaths and 65,561 recoveries, Polandin.com said.